Aims and objectives of this presentation
The treatment Castration Resistant Prostate Cancer has been revolutionised over the years. Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)


Institutes: Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, Hospital Universitario Reina Sofia, Dept. of Medical Oncology, Cordoba, Spain, Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, Rambam Medical Center, Dept. of Oncology, Haifa, Israel, Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, Romagnolo Scientific Institute For The Study and Care of Cancer – IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial

By: Fizazi K., Massard C., Bono P., Kataja V., James N., Tammela T., Joensuu H., Aspegren J., Mustonen M.V.

Institutes: Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, Tampere University Hospital, Dept. of Urology, Tampere, Finland, Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

Statin use and prostate cancer mortality

By: Benzon Larsen S., Skriver C., Dehlendorff C., Jespersen C., Borre M., Nørgård M., Brasso K., Andersen K.K., Sørensen H., Hallas J., Friis S.

Institutes: Danish Cancer Society, Research Centre, Copenhagen, Denmark, Viborg Hospital, Dept. of Urology, Viborg, Denmark, Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark
Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy  
By: Shuhei K.1, Sakamoto S.2, Yamamoto S.1, Inoue T.1, Nozumi K.1, Chiba K.1, Miyazaki K.1, Atsushi I.1, Nagata M.1  
Institutes: Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan, Chiba Univ. Hospital, Dept. of Urology, Chiba, Chiba, Japan

Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime  
By: Hammerer P.1, Al-Batran S-E.2, Windemuth-Kieselbach C.3, Hofheinz R-D.4  
Institutes: 1Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany, 2Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany, 3Alcedis GmbH, Dept. of Biometry, Gießen, Germany, 4University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany

Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer  
By: Heck M.M.1, Retz M.1, Rauscher I.2, Scheidhauer K.2, Maurer T.1, Storz E.1, Janssen F.1, D’Alessandria C.1, Wester H.-J.3, Gschwend J.E.1, Schwaiger M.2, Tauber R.1, Eiber M.2  
Institutes: Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, Klinikum Rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany, Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany

Hormonal response after long-term androgen suppression in patients with prostate cancer  
By: Planas Morin J.1,1, Cemla A.1, Regis L.1, Cuadras M.1, Trilla E.1, Salvador C.1, Placer J.1, Lorente D.1, Carles J.2, Suárez C.2, Morote J.1  
Institutes: Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain, Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain

Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases  
Institutes: Chu Brugmann, Dept. Of Medicine, Brussels, Belgium, Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland, Adelphi Real World, Bollington, United Kingdom, Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America, Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland

Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?  
Institutes: Ghent University Hospital, Dept. of Urology, Ghent, Belgium, Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium, Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium, AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium, AZ Klinia, Dept. of Medical Oncology, Brasschaat, Belgium, AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium, AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium, Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium, OLV Aalst, Dept. of Urology, Aalst, Belgium, Hopital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium, Cliniques Universitaires Saint Luc, Dept. of
**Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database**

By: Mohamad Al-Ali B.1, Madersbacher S.1, Berger I.2

Institutes: 1Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, 2Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

**ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)**

By: Todenhöfer T.1, Azad A.2, Gao J.1, Stewart C.1, Eigl B.2, Stenzl A.4, Black P.1, Teich M.3, Joshua A.3, Chi K.2

Institutes: University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, 2British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, 3University of Toronto, Princess Margret Cancer Centre, Toronto, Canada, 4Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

**The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naive metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)**

By: Miller K.1, Carles J.5, Gschwend J.E.3, Van Poppel H.4, Diels J.5, Brookman-May S.D.6

Institutes: 1Charité Berlin, Dept. of Urology, Berlin, Germany, 2Vall D'Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, 3Technical University of Munich, School of Medicine, Munich, Germany, 4Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, 5Janssen EMEA, HEMAR, Beerse, Belgium, 6Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany